Matching articles for "prothrombin complex concentrates"
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
The Medical Letter on Drugs and Therapeutics • February 19, 2024; (Issue 1696)
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent...
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent surgical/invasive procedure. It is the second
four-factor PCC to become available in the US;
Kcentra, which has been available since 2013, is
approved for the same indication and for urgent
reversal of warfarin anticoagulation in adults with
acute major bleeding. Balfaxar is marketed in Canada
and Europe as Octaplex.
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • July 25, 2022; (Issue 1655)
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.
Which Oral Anticoagulant for Atrial Fibrillation?
The Medical Letter on Drugs and Therapeutics • April 11, 2016; (Issue 1492)
Direct-to-consumer advertisements continue to
urge patients who take warfarin (Coumadin, and
others) for atrial fibrillation to ask their doctors
about the benefits of one or another of the newer
oral...
Direct-to-consumer advertisements continue to
urge patients who take warfarin (Coumadin, and
others) for atrial fibrillation to ask their doctors
about the benefits of one or another of the newer
oral anticoagulants.
Kcentra: A 4-Factor Prothrombin Complex Concentrate for Reversal of Warfarin Anticoagulation
The Medical Letter on Drugs and Therapeutics • July 8, 2013; (Issue 1420)
The FDA has approved use of Kcentra (CSL Behring), a
human-derived 4-factor prothrombin complex concentrate
(PCC), for urgent reversal of warfarin anticoagulation
in adults with acute major bleeding. It is...
The FDA has approved use of Kcentra (CSL Behring), a
human-derived 4-factor prothrombin complex concentrate
(PCC), for urgent reversal of warfarin anticoagulation
in adults with acute major bleeding. It is the only
4-factor PCC available in the US.
Prothrombin Complex Concentrates to Reverse Warfarin-Related Bleeding
The Medical Letter on Drugs and Therapeutics • October 3, 2011; (Issue 1374)
Warfarin-related bleeding, especially intracranial hemorrhage,
can be catastrophic. Several products are available
to reverse warfarin’s anticoagulant...
Warfarin-related bleeding, especially intracranial hemorrhage,
can be catastrophic. Several products are available
to reverse warfarin’s anticoagulant effect.